323 related articles for article (PubMed ID: 32081368)
1. Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor.
Sun MT; Huang S; Wiviott SD; Antman EM; Roe MT; Ohman EM; Neely M; Wallentin L; Wong CX
Am J Cardiol; 2020 Apr; 125(8):1280-1283. PubMed ID: 32081368
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of High Potent P2Y
Schreuder MM; Badal R; Boersma E; Kavousi M; Roos-Hesselink J; Versmissen J; Visser LE; Roeters van Lennep JE
J Am Heart Assoc; 2020 Feb; 9(4):e014457. PubMed ID: 32063118
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y
Franchi F; Rollini F; Faz G; Rivas JR; Rivas A; Agarwal M; Briceno M; Wali M; Nawaz A; Silva G; Shaikh Z; Maaliki N; Fahmi K; Been L; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Baber U; Mehran R; Jennings LK; Bass TA; Angiolillo DJ
J Am Heart Assoc; 2020 Apr; 9(8):e015865. PubMed ID: 32306797
[TBL] [Abstract][Full Text] [Related]
4. The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y
O'Donoghue ML; Murphy SA; Sabatine MS
Circulation; 2020 Aug; 142(6):538-545. PubMed ID: 32551860
[TBL] [Abstract][Full Text] [Related]
5. Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review.
Kamran H; Jneid H; Kayani WT; Virani SS; Levine GN; Nambi V; Khalid U
JAMA; 2021 Apr; 325(15):1545-1555. PubMed ID: 33877270
[TBL] [Abstract][Full Text] [Related]
6. Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population.
Hou M; Hyun K; Chew DP; Kritharides L; Amos D; Brieger D
Heart Lung Circ; 2022 Aug; 31(8):1085-1092. PubMed ID: 35589483
[TBL] [Abstract][Full Text] [Related]
7. Meta-Analysis Comparing P2Y
Baldetti L; Melillo F; Moroni F; Gallone G; Pagnesi M; Venuti A; Beneduce A; Calvo F; Gramegna M; Godino C; D'Ascenzo F; De Ferrari GM; Capodanno D; Cappelletti AM
Am J Cardiol; 2020 Jun; 125(12):1815-1822. PubMed ID: 32305225
[TBL] [Abstract][Full Text] [Related]
8. Antiplatelet Therapy in Elderly Patients with Acute Coronary Syndromes: the Clopidogrel Revenge: Possible Reasons for a Bright Comeback.
De Servi S; Landi A; Savonitto S
Cardiovasc Drugs Ther; 2021 Apr; 35(2):399-401. PubMed ID: 32809109
[No Abstract] [Full Text] [Related]
9. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
Westman PC; Lipinski MJ; Torguson R; Waksman R
Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
[TBL] [Abstract][Full Text] [Related]
10. P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials.
Song PS; Park YH; Oh JH; Song YB; Choi SH; Gwon HC; Cho DK; Rha SW; Bae JW; Jeong JO; Hahn JY;
Am J Cardiol; 2021 Jul; 150():47-54. PubMed ID: 34011436
[TBL] [Abstract][Full Text] [Related]
11. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
[TBL] [Abstract][Full Text] [Related]
12. Monotherapy with a P2Y
Chiarito M; Sanz-Sánchez J; Cannata F; Cao D; Sturla M; Panico C; Godino C; Regazzoli D; Reimers B; De Caterina R; Condorelli G; Ferrante G; Stefanini GG
Lancet; 2020 May; 395(10235):1487-1495. PubMed ID: 32386592
[TBL] [Abstract][Full Text] [Related]
13. Course of platelet miRNAs after cessation of P2Y12 antagonists.
Jäger B; Stojkovic S; Haller PM; Piackova E; Kahl BS; Andric T; Vargas KG; Wojta J; Huber K
Eur J Clin Invest; 2019 Aug; 49(8):e13149. PubMed ID: 31172515
[TBL] [Abstract][Full Text] [Related]
14. Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?
Guimarães PO; Tricoci P
Expert Opin Pharmacother; 2015; 16(13):1983-95. PubMed ID: 26224244
[TBL] [Abstract][Full Text] [Related]
15. Frequency and Reasons of Dual Antiplatelet Therapy Discontinuation and Switching of P2Y12 Inhibitors in Patients with Acute Coronary Syndrome Treated with Stent Implantation.
Fuertes Ferre G; Caballero Jambrina I; Ruiz Aranjuelo A; Jimeno Sánchez J; Galache Osuna JG; Andrés Esteban EM; Casasnovas Lenguas JA; Diarte de Miguel JA
Cardiology; 2019; 142(4):203-207. PubMed ID: 31266007
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet treatments: recent evidence from randomized controlled trials.
Vogel B; Baber U
Curr Opin Cardiol; 2017 Jul; 32(4):356-362. PubMed ID: 28463894
[TBL] [Abstract][Full Text] [Related]
17. P2Y
van der Sangen NM; Küçük IT; Ten Berg JM; Beijk MA; Delewi R; den Hartog AW; Appelman Y; Verouden NJ; Kikkert WJ; Henriques JP; Claessen BE
Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):637-645. PubMed ID: 35916833
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of new P2Y12 inhibitors: selection of P2Y12 inhibitors in clinical practice.
Golino P
J Cardiovasc Med (Hagerstown); 2013 Dec; 14 Suppl 1():S22-30. PubMed ID: 24378838
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction.
Dimitroulis D; Golabkesh M; Naguib D; Knoop B; Dannenberg L; Helten C; Pöhl M; Jung C; Kelm M; Zeus T; Polzin A
J Cardiovasc Pharmacol; 2018 Oct; 72(4):186-190. PubMed ID: 29985284
[TBL] [Abstract][Full Text] [Related]
20. Duration of Dual Antiplatelet Therapy in the Post-Acute Coronary Syndrome Patient.
Bobadilla RV
J Cardiovasc Nurs; 2018; 33(3):248-254. PubMed ID: 29251650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
